Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)

J. J. Knox; C. H. Barrios; T. M. Kim; T. Cosgriff; V. Srimuninnimit; K. Pittman; R. Sabbatini; S. Y. Rha; T. W. Flaig; R. D. Page; J. T. Beck; F. Cheung; S. Yadav; P. Patel; L. Geoffrois; J. Niolat; N. Berkowitz; M. Marker; D. Chen; R. J. Motzer

doi:10.1093/annonc/mdx807

Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)

J. J. Knox, C. H. Barrios, T. M. Kim, T. Cosgriff, V. Srimuninnimit, K. Pittman, R. Sabbatini, S. Y. Rha, T. W. Flaig, R. D. Page, J. T. Beck, F. Cheung, S. Yadav, P. Patel, L. Geoffrois, J. Niolat, N. Berkowitz, M. Marker, D. Chen, R. J. Motzer

Department of Internal Medicine

Research output: Contribution to journal › Comment/debate › peer-review

3 Citations (Scopus)

Abstract

In the original article, Figure 2B incorrectly described the curves as PFS, while it should have read OS. This has now been corrected.

Original language	English
Article number	2269
Journal	Annals of Oncology
Volume	29
Issue number	11
DOIs	https://doi.org/10.1093/annonc/mdx807
Publication status	Published - 2018 Nov

Bibliographical note

Publisher Copyright:
© The Author(s) 2018.

All Science Journal Classification (ASJC) codes

Hematology
Oncology

Access to Document

10.1093/annonc/mdx807

Fingerprint

Dive into the research topics of 'Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)'. Together they form a unique fingerprint.

Cite this

Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Rha, S. Y., Flaig, T. W., Page, R. D., Beck, J. T., Cheung, F., Yadav, S., Patel, P., Geoffrois, L., Niolat, J., Berkowitz, N., Marker, M., Chen, D., & Motzer, R. J. (2018). Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075). Annals of Oncology, 29(11), Article 2269. https://doi.org/10.1093/annonc/mdx807

@article{e619c1495623493da94557df5f2ff241,

title = "Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)",

abstract = "In the original article, Figure 2B incorrectly described the curves as PFS, while it should have read OS. This has now been corrected.",

author = "Knox, {J. J.} and Barrios, {C. H.} and Kim, {T. M.} and T. Cosgriff and V. Srimuninnimit and K. Pittman and R. Sabbatini and Rha, {S. Y.} and Flaig, {T. W.} and Page, {R. D.} and Beck, {J. T.} and F. Cheung and S. Yadav and P. Patel and L. Geoffrois and J. Niolat and N. Berkowitz and M. Marker and D. Chen and Motzer, {R. J.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2018.",

year = "2018",

month = nov,

doi = "10.1093/annonc/mdx807",

language = "English",

volume = "29",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "11",

}

Knox, JJ, Barrios, CH, Kim, TM, Cosgriff, T, Srimuninnimit, V, Pittman, K, Sabbatini, R, Rha, SY, Flaig, TW, Page, RD, Beck, JT, Cheung, F, Yadav, S, Patel, P, Geoffrois, L, Niolat, J, Berkowitz, N, Marker, M, Chen, D & Motzer, RJ 2018, 'Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)', Annals of Oncology, vol. 29, no. 11, 2269. https://doi.org/10.1093/annonc/mdx807

Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075). / Knox, J. J.; Barrios, C. H.; Kim, T. M. et al.
In: Annals of Oncology, Vol. 29, No. 11, 2269, 11.2018.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Erratum

T2 - Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)

AU - Knox, J. J.

AU - Barrios, C. H.

AU - Kim, T. M.

AU - Cosgriff, T.

AU - Srimuninnimit, V.

AU - Pittman, K.

AU - Sabbatini, R.

AU - Rha, S. Y.

AU - Flaig, T. W.

AU - Page, R. D.

AU - Beck, J. T.

AU - Cheung, F.

AU - Yadav, S.

AU - Patel, P.

AU - Geoffrois, L.

AU - Niolat, J.

AU - Berkowitz, N.

AU - Marker, M.

AU - Chen, D.

AU - Motzer, R. J.

PY - 2018/11

Y1 - 2018/11

N2 - In the original article, Figure 2B incorrectly described the curves as PFS, while it should have read OS. This has now been corrected.

AB - In the original article, Figure 2B incorrectly described the curves as PFS, while it should have read OS. This has now been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85058593544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058593544&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx807

DO - 10.1093/annonc/mdx807

M3 - Comment/debate

C2 - 29390043

AN - SCOPUS:85058593544

SN - 0923-7534

VL - 29

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

M1 - 2269

ER -

Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K et al. Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075). Annals of Oncology. 2018 Nov;29(11):2269. doi: 10.1093/annonc/mdx807

Erratum: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (Annals of Oncology (2017) 28 (1339–1345) DOI: 10.1093/annonc/mdx075)

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this